Dekeyne A, Girardon S, Millan M J
Institut de Recherches Servier, Psychopharmacology Department, Paris, France.
Neuropharmacology. 1999 Mar;38(3):415-23. doi: 10.1016/s0028-3908(98)00203-2.
Employing a Fixed-Ratio 10, food-reinforced protocol, rats were trained to recognize the discriminative stimulus (DS) properties of the novel, potent, 5-HT2C agonist, Ro 60-0175 (2.5 mg/kg, i.p.). This schedule generated appropriate drug versus vehicle responding after 50 + 5 training sessions and Ro 60-0175 elicited full (100%) drug selection with an effective dose50 (ED50) of 0.6 mg/kg, i.p.. The 5-HT2C receptor agonists, mCPP and MK 212, fully generalized to Ro 60-0175 with ED50s of 0.8 and 0.4 mg/kg, s.c., respectively, whereas the preferential 5-HT2B agonist, BW 723C86 ( > 10.0 mg/kg, s.c.) and the 5-HT2A agonist, DOI ( > 2.5 mg/kg, s.c.), were ineffective. The 5-HT2A/2B/2C receptor antagonist, mianserin, dose-dependently blocked the DS properties of Ro 60-0175 with an ED50 of 0.7 mg/kg, s.c. This action was mimicked by the novel, 5-HT2B/2C antagonist, SB 206,553 (ED50 = 0.3 mg/kg, s.c.), whereas the selective 5-HT2A antagonist, MDL 100,907 ( > 0.63 mg/kg, s.c.), was ineffective. Further, the selective 5-HT2C antagonist, SB 242,084, dose-dependently and fully blocked drug selection (ED50 = 0.2 mg/kg, i.p.), whereas the selective 5-HT2B antagonist, SB 204,741, was not active ( > 0.63 mg/kg, i.p.). In conclusion, these data demonstrate that Ro 60-0175 generates a robust DS and suggest that activation of 5-HT2C receptors is the principal mechanism underlying its DS properties.
采用固定比率10、食物强化方案,训练大鼠识别新型强效5-HT2C激动剂Ro 60-0175(2.5毫克/千克,腹腔注射)的辨别刺激(DS)特性。该方案在50 + 5次训练后产生了适当的药物与赋形剂反应,Ro 60-0175以0.6毫克/千克的半数有效剂量(ED50)腹腔注射时引发了完全(100%)的药物选择。5-HT2C受体激动剂mCPP和MK 212分别以0.8毫克/千克和0.4毫克/千克的皮下注射ED50完全泛化至Ro 60-0175,而优先的5-HT2B激动剂BW 723C86(>10.0毫克/千克,皮下注射)和5-HT2A激动剂DOI(>2.5毫克/千克,皮下注射)无效。5-HT2A/2B/2C受体拮抗剂米安色林以0.7毫克/千克的皮下注射ED50剂量依赖性地阻断Ro 60-0175的DS特性。这种作用被新型5-HT2B/2C拮抗剂SB 206,553(ED50 = 0.3毫克/千克,皮下注射)模拟,而选择性5-HT2A拮抗剂MDL 100,907(>0.63毫克/千克,皮下注射)无效。此外,选择性5-HT2C拮抗剂SB 242,084剂量依赖性地完全阻断药物选择(ED50 = 0.2毫克/千克,腹腔注射),而选择性5-HT2B拮抗剂SB 204,741无活性(>0.63毫克/千克,腹腔注射)。总之,这些数据表明Ro 60-0175产生了强大的DS,并表明5-HT2C受体的激活是其DS特性的主要潜在机制。